Literature DB >> 29572549

Mechanistic insights into cancer immunity and immunotherapy.

Weiping Zou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29572549      PMCID： PMC6068178          DOI： 10.1038/s41423-018-0011-5

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  21 in total

Review 1.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

2.  Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.

Authors:  Khashayar Esfahani; Wilson H Miller
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 4.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

5.  The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells.

Authors:  Chrystal M Paulos; Carmine Carpenito; Gabriela Plesa; Megan M Suhoski; Angel Varela-Rohena; Tatiana N Golovina; Richard G Carroll; James L Riley; Carl H June
Journal:  Sci Transl Med       Date:  2010-10-27       Impact factor: 17.956

Review 6.  The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates.

Authors:  Eslam Mohamed; Amir A Al-Khami; Paulo C Rodriguez
Journal:  Cell Mol Immunol       Date:  2018-03-22       Impact factor: 11.530

Review 7.  When worlds collide: Th17 and Treg cells in cancer and autoimmunity.

Authors:  Hannah M Knochelmann; Connor J Dwyer; Stefanie R Bailey; Sierra M Amaya; Dirk M Elston; Joni M Mazza-McCrann; Chrystal M Paulos
Journal:  Cell Mol Immunol       Date:  2018-03-21       Impact factor: 11.530

8.  Th17 cells are long lived and retain a stem cell-like molecular signature.

Authors:  Pawel Muranski; Zachary A Borman; Sid P Kerkar; Christopher A Klebanoff; Yun Ji; Luis Sanchez-Perez; Madhusudhanan Sukumar; Robert N Reger; Zhiya Yu; Steven J Kern; Rahul Roychoudhuri; Gabriela A Ferreyra; Wei Shen; Scott K Durum; Lionel Feigenbaum; Douglas C Palmer; Paul A Antony; Chi-Chao Chan; Arian Laurence; Robert L Danner; Luca Gattinoni; Nicholas P Restifo
Journal:  Immunity       Date:  2011-12-15       Impact factor: 31.745

Review 9.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

Review 10.  IDO1 in cancer: a Gemini of immune checkpoints.

Authors:  Lijie Zhai; Erik Ladomersky; Alicia Lenzen; Brenda Nguyen; Ricky Patel; Kristen L Lauing; Meijing Wu; Derek A Wainwright
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530
View more
  14 in total

1.  N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.

Authors:  Zhang Meijing; Luo Tianhang; Yang Biao
Journal:  Front Cell Dev Biol       Date:  2022-06-15

2.  Unsupervised capture and profiling of rare immune cells using multi-directional magnetic ratcheting.

Authors:  Coleman Murray; Hiromi Miwa; Manjima Dhar; Da Eun Park; Edward Pao; Jessica Martinez; Sireesha Kaanumale; Evelina Loghin; John Graf; Khadir Raddassi; William W Kwok; David Hafler; Chris Puleo; Dino Di Carlo
Journal:  Lab Chip       Date:  2018-08-07       Impact factor: 6.799

3.  MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies.

Authors:  Srividya Swaminathan; Aida S Hansen; Line D Heftdal; Renumathy Dhanasekaran; Anja Deutzmann; Wadie D M Fernandez; Daniel F Liefwalker; Crista Horton; Adriane Mosley; Mariola Liebersbach; Holden T Maecker; Dean W Felsher
Journal:  Nat Commun       Date:  2020-06-05       Impact factor: 14.919

Review 4.  NK Cell Dysfunction and Checkpoint Immunotherapy.

Authors:  Jiacheng Bi; Zhigang Tian
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

5.  Technical advances in NK cell-based cellular immunotherapy.

Authors:  Fang Fang; Wei Wang; Minhua Chen; Zhigang Tian; Weihua Xiao
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

6.  Enhanced Anti-melanoma Efficacy of a Pim-3-Targeting Bifunctional Small Hairpin RNA via Single-Stranded RNA-Mediated Activation of Plasmacytoid Dendritic Cells.

Authors:  Jing Liu; Yuan Hu; Qie Guo; Xin Yu; Liwei Shao; Cai Zhang
Journal:  Front Immunol       Date:  2019-11-26       Impact factor: 7.561

Review 7.  The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.

Authors:  Haoyu Sun; Cheng Sun
Journal:  Front Immunol       Date:  2019-10-17       Impact factor: 7.561

Review 8.  Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.

Authors:  Natasha Mupeta Kaweme; Fuling Zhou
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

Review 9.  The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.

Authors:  Yuxia Liu; Cai Zhang
Journal:  Cells       Date:  2020-05-13       Impact factor: 6.600

Review 10.  Targeting Natural Killer Cells for Tumor Immunotherapy.

Authors:  Cai Zhang; Yuan Hu; Chongdeng Shi
Journal:  Front Immunol       Date:  2020-02-19       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.